Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.40 |
| ▸ | LSS | P48449 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL5650192 | 1.00 | LSS (0.50) | LSSCYP2D6CHRNA7BCHEACHE | |
| SCHEMBL5440796 | 0.89 | LSS (0.50) | LSSCYP2D6CHRNA7NPC1RAB9A | |
| Fumaric Acid SCHEMBL5420571 | 0.80 | CHRNA7 (0.50) | LSSCYP2D6CHRNA7BCHEACHE | |
| Fumaric Acid SCHEMBL5420562 | 0.80 | CHRNA7 (0.50) | LSSCYP2D6CHRNA7BCHEACHE | |
| Fumaric Acid SCHEMBL5650250 | 0.79 | LSS (0.54) | LSSCHRNA7BCHEACHECHRM3 | |
| Fumaric Acid SCHEMBL5650257 | 0.79 | LSS (0.54) | LSSCHRNA7BCHEACHECHRM3 | |
| Fumaric Acid SCHEMBL1020193 | 0.78 | LSS (0.53) | LSSCHRNA7BCHEACHECHRM3 | |
| Fumaric Acid SCHEMBL5430235 | 0.77 | LSS (0.47) | LSSCHRNA7BCHEACHENPC1 | |
| Fumaric Acid SCHEMBL5430247 | 0.77 | LSS (0.47) | LSSCHRNA7BCHEACHENPC1 | |
| Fumaric Acid SCHEMBL1796669 | 0.77 | LSS (0.49) | LSSCHRNA7BCHEACHEMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241773-B2 | 3-quinuclidinyl heteroatom bridged biaryl derivatives | ABBOTT LABORATORIES (US) | 2007-07-10 | — | — | US | disclosed |
| US-20050137226-A1 | 3-Quinuclidinyl heteroatom bridged biaryl derivatives | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | disclosed |
| US-20050137398-A1 | 3-Quinuclidinyl heteroatom bridged biaryl derivatives | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137398-A1 | 3-Quinuclidinyl heteroatom bridged biaryl derivatives | CHRNA1, CHRNA2, CHRM2 | CHRM3 6/4885LSS 2314/4885CYP2D6 452/4885 |
| US-20050137226-A1 | 3-Quinuclidinyl heteroatom bridged biaryl derivatives | CHRNA3, CHRNA1, CHRM3 | CHRM3 3/4885LSS 1730/4885CYP2D6 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.